From October 2014 to December 2019, in the uncommon EGFR mutation-positive NSCLC group, the median OS was 34.6 months (95% CI: 16.0–35.2) for afatinib and 15.5 months (95% CI: 9.0–22.0) for gefitinib or erlotinib (Table 2 and Figure 1B) (p = 0.03). This evidence concerns the gene EGFR and non-small cell lung carcinoma.